The molecule, Itolizumab, is the second biologic the company has developed in India after BioMab EGFR, an anti-cancer monoclonal antibody. With the marketing authorisation from the Drugs Controller General of India, the company plans to roll out a drug, Alzumab, for the skin ailment later this year. It plans to manufacture Alzumab at Bangalore.
This approval paves the way for us to extend clinical development for other indications. We also intend to file a US IND (investigational new drug) shortly to enable us to embark on a global clinical development plan, said Kiran Mazumdar-Shaw, CMD, Biocon.